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Glycosylation is one of the most common posttranslational modiﬁcation reactions and nearly half of all known proteins in
eukaryotes are glycosylated. In fact, changes in oligosaccharides structures are associated with many physiological and pathological
events, including cell growth, migration and diﬀerentiation, and tumor invasion. Therefore, functional glycomics, which is a
comprehensive study of the structures and functions of glycans, is attracting the increasing attention of scientists in various
ﬁelds of life science. In cases of thyroid cancer, the biological characters and prognosis are completely diﬀerent in each type of
histopathology,andtheiroligosaccharidestructuresaswellastheexpressionofglycosyltransferasesarealsodiﬀerent.Inthisreview,
we summarized our previous papers on oligosaccharides and thyroid cancers and discussed a possible function of oligosaccharides
in the carcinogenesis in thyroid cancer.
1.Introduction
Oligosaccharides are mostly found on the cell surface and
extracellular matrix (ECM), and also in various organelles
such as the Golgi, ER, lysosome, cytosol, and nuclei. As
compared to research on DNA, RNA, and proteins, study
on glycans is rather diﬃcult and the research in this ﬁeld
has been neglected for a long period, the same being
true for glycomics as compared to proteomic research. In
order to characterize the structures of glycans, glycobiology
including glycomics is essential for understanding of the
structures and functions of proteins. In the last couple of
years, most of the glycosyltransferases (over 180 glycosyl-
transferase genes) have been identiﬁed, based on the genome
sequence data and bioinformatics approach. Glycosylation
reactions are catalyzed by the actions of glycosyltransferases;
sugar chains are added to various complex carbohydrates.
Modiﬁed oligosaccharides have the ability to interfere with
carbohydrate-protein or protein/glycoprotein-glycoprotein
interactions and, as a result, regulate many physiological
and pathological events, including cell growth, migration
and diﬀerentiation, and tumor metastasis. Cell surface
carbohydrates contribute to a variety of interactions between
a cell and its extracellular environment, since they are
located on the outermost layer of the cell. Carbohydrates
are the ﬁrst molecules to be encountered and recognized
by other cells, antibodies, invading viruses, and bacteria.
Many secreted molecules such as hormones and toxins have
also been reported to bind to carbohydrate receptors on
the cell surface. Most receptors on the cell surface are
N-glycosylated, including epithelial growth factor recep-
tor (EGFR), integrins, and transforming growth factor β
receptor (TGFβ R). Increasing evidence indicates that sugar
chains on glycoproteins are involved in the regulation of
cell-cell communication, signal transduction, and protein
folding and stability [2–5]. During the carcinogenesis in
thyroid cancer, the biological characteristics of tumor cells
dramatically changed with malignant transformation into
undiﬀerentiatedthyroidcancer.Inthisperiod,theexpression
of glycosyltransferases as well as their target proteins would
also be altered. The alteration of oligosaccharide structures
on the cell surface could control cellular diﬀerentiation
and biological characteristics. Also, aberrant expression of
g l y c o - r e l a t e dg e n e sc o u l db eam a r k e ro ft h y r o i dc a n c e r .2 Journal of Oncology
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Figure 1: Oligosaccharide-related molecules in this review. (a) Reaction pathway catalyzed by Fut8. Expression of Fut8 was increased at
the early phase of carcinogenesis and decreased at the advanced stage. (b) Reaction pathway catalyzed by GnT-V. Expression of GnT-V was
up-regulated in a two-step manner. (c) Structure of GPC3. GPC 3 is a proteoglycan with two oligosaccharides at the 494 and 508 amino acid
residues and binds to cell membranes through a GPI-anchor. GPC3-deﬁcient mice showed overgrowth a14-day embryo stage.
In this review, we mainly focus on the importance of
oligosaccharides in thyroid cancer, according to our previous
reports.
2. Why Did WeStarta Glycomics Project?
Glycobiology is one of the most diﬃcult research areas in life
science because oligosaccharides exhibit a variety of aspects
and their functions often diﬀer with the organ, species, or
type of cancer. In terms of cancer, prominent changes in
oligosaccharide structures on glycoproteins are dependent
on sialylation, fucosylation, and branching formation. Both
sialylation and fucosylation modify the charges on total
oligosaccharide structures and thus controll receptor and
adhesion molecules on the cell surface. Sialylation of IgG
oligosaccharides can regulate allergic reactions and this
minor IgG group suppresses autoimmuno reactions [6, 7].
Fucosylation is one of the most important oligosaccharide
modiﬁcations, being linked to cancer and inﬂammation [8].
Manyreportshaveimpliedtheinvolvementofbranchingfor-
mation of N-glycans and N-acetylglucosaminyltransferase
V (GnT-V) which is key enzymes producing the branching
[9]. Regarding many biological phenomena, Dr Taniguchi’s
group have succeeded in the puriﬁcation and character-
ization of glycosyltransferases, which are involved in the
branching formation for N-glycans [10]. Involving cDNAs
or antibodies for these glycosyltransferases, many studies
have revealed the relationship to carcinogenesis and/or
tumor metastasis. Figure 1 shows three targets of glyco-
related proteins in this review. Basically, the expression
of Fut8 and GnT-V is relatively low and increases with
malignant transformation. Expression of Fut8 increases in
the early phase of carcinogenesis, but decreases at the stage
of metastasis. In contrast, two-step increases in GnT-V
expressionareobservedincertainkindsofcancer.Expression
of glypican 3, which is a proteoglycan belonging to the
glypican family, increases/decreases in an organ-speciﬁc
manner.Journal of Oncology 3
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Figure 2: Immunohistochemical studies on Fut8, GnT-V, and GPC3 in thyroid cancer. The staining of Fut8 was located in the Golgi
apparatus, while GnT-V staining was observed throughout a cell. Staining of GPC3 was heterogeneous and showed a membrane pattern.
3. Fut8and Thyroid Cancer
Fucosylation is one of the most important modes of glyco-
sylation in cancer. Fucosylation is regulated by several kinds
of fucosyltransferases, the GDP-fucose synthetic pathway
and GDP-fucose transporters. Before these complicated
mechanisms of fucosylation were clariﬁed, fucosylated target
proteins were found and used as tumor markers. Increases
in fucosylated alpha-fetoprotein (AFP) were reported by
Drs Breborowicz et al. [11] and Dr Taketa et al. [12].
They ﬁrst found microheterogeneity of AFP in several liver
conditions and then found increases in α1-6 fucosylation
(core-fucosylation) of AFP on lectin aﬃno-electrophoresis.
AFP is a well-known tumor marker for hepatocellular
carcinomas (HCCs), but it is sometimes also increased in
benign liver diseases such as chronic hepatitis and liver
cirrhosis. In contrast, AFP with core-fucosylation is a very
speciﬁcmarkerofHCCs[13,14].AFPwithcore-fucosylation
was called AFP-L3, because it was detected in the L3 fraction
on LCA (Lens culinaris agglutinin) lectin-electorophoresis.
Core-fucosylation comprises the attachment of fucose to the
innermost N-acetylglucosamine in N-glycans. α1-6 fucosyl-
transferase (Fut8) catalyzes this core-fucosylation reaction.
Dr. Uozumi et al. succeeded in the puriﬁcation and cDNA
cloning of Fut8 from porcine brain [15]. Studies on cancer
and fucosylation have moved to the second stage since that
time. Fut8 knockout mice show emphysema-like lesions in
the lungs because core-fucose is important for the functions
of reactions such as EGF-R and TGFβ-R [5, 16]. When we
established a monoclonal antibody for Fut8, we performed
the ﬁrst immunohistochemical study on thyroid cancer [17].
This is because there are various types of thyroid cancer and
the prognosis diﬀers for each pathological condition. As a
result of immunohistochemical studies, involving 133 cases
of thyroid cancer, the expression of Fut8 was found to be
quite low in normal follicles. As shown in Figure 2,p o s i t i v e
staining of Fut8 was observed in papillary carcinomas. This
staining pattern could be called Golgi localization. The
number of Fut8-positive cases of follicular carcinomas was
relatively low. We concluded that expression of Fut8 might
be a key factor for the progression of thyroid papillary carci-
nomas, but not of follicular carcinomas. High expression of
Fut8 was observed in 33.3% of papillary carcinomas and the
incidence was directly linked to tumor size and lymph node
metastasis. In contrast, this phenomenon was less frequently
observed in cases of follicular carcinomas and anaplastic
(undiﬀerentiated) carcinomas. Furthermore, decreases in
Fut8 expression in papillary carcinomas might be linked to
anaplastic transformation. These results seem to be similar
to the results in the case of colon carcinogenesis that
is, “fucosylation and defucosylation” [18]. Further studies
should determine the biological function of core-fucose in
thyroid cancer.
4. GnT-V and ThyroidCancer
N-Acetylglucosaminyltransferase V (GnT-V) is one of the
most important glycosyltransferases in tumor metastasis
[9] .S of a r ,m o r et h a n8 0p a p e r so nG n T - Va n dt u m o r
metastasis have appeared, with this number being quite high
as compared to other glycosyltransferases. One mechanism4 Journal of Oncology
H
e
p
G
2
H
e
p
3
B
T
A
D
-
m
o
c
k
T
A
D
2
-
m
u
t
a
n
t
G
P
C
3
T
A
D
2
-
w
i
l
d
G
P
C
3
TAD-mock TAD2-mutant GPC3 TAD2-wild GPC3
(b)
(a)
02 4 4 87 2 9 6
(hours)
Control
Mutant
Wild
R
e
l
a
t
i
v
e
c
e
l
l
n
u
m
b
e
r
(c)
Figure 3: The eﬀect of overexpression of GPC3 with/without oligosaccharides on thyroid cancer cell lines. Western blot analysis of GPC3
was performed using cellular proteins derived from HepG2 cells, Hep3B cells, parental TAD2 cells, mutant GPC3-transfected TAD2 cells,
and wild type GPC3-transfected TAD2 cells. (b) Microscopic observation of parental TAD2 cells, wild type GPC3-transfected TAD2 cells,
and mutant GPC3-transfected TAD2 cells. Morphological changes were observed for wild type GPC3-transfected TAD2 cells, as compared
to the other two types of cells. (c) Cell proliferation was evaluated by means of WST-1 assaying.
underlying GnT-V and tumor progression is beta1-6 GlcNAc
branching formation, a product of GnT-V, up-regulating cell
surface growth factor receptors such as EGF-R [19]. The
other mechanism is suppressing of the degradation of glyco-
proteins, resulting in an increase in protease expression [20].
Matriptase is a tumor-associated type II transmembrane
serine protease thatpositively regulatescarcinoma metastasis
by activating the latent forms of hepatocyte growth factor
(HGF) and urokinase-type plasminogen activator (uPA)
[21]. The overexpression of GnT-V in gastric carcinoma cells
enhances the degradation of matriptase and accelerated the
peritoneal dissemination of these cancer cells in athymic
mice [20]. Matriptase puriﬁed from GnT-V-transfected
gastric cancer cells is resistant to trypsin and this resistance
is dependent on the oligosaccharides linked to the 772 Asn
residue of matriptase [22]. These ﬁndings indicate that GnT-
V modiﬁes the oligosaccharide structure of matriptase, thus
altering the function of proteases. According to the results
of these in vitro studies on GnT-V and matriptase, we
performed immunohistochemical studies, using 132 cases of
thyroid cancers [23]. While neither GnT-V nor matriptase
was expressed in normal thyroid tissue, positive staining for
matriptaseandGnT-Vwasobservedin52/68and66/68cases
of papillary carcinomas, 3/23 and 10/23 cases of follicular
carcinomas, 5/13 and 9/13 cases of follicular adenomas, and
11/28 and 6/28 cases of anaplastic carcinomas, respectively.
Immunohistochemistry, as well as Western blotting, showed
that the expression of matriptase paralleled the expression
of GnT-V. However, the expression of matriptase mRNA
was not correlated with its protein level, suggesting that the
enhancement of matriptase expression could be caused by a
posttranslational modiﬁcation such as glycosylation through
GnT-V-mediated glycosylation. In the case of papillary
carcinomas, the levels of expression of both GnT-V and
matriptase were signiﬁcantly higher in tumors of 1cm or
less in size (microcarcinomas) and in cases without poorly
diﬀerentiated lesions, and the two proteins were signiﬁcantly
correlated. In contrast, the prognosis of thyroid carcinomas
after surgery was correlated with the expression of neither
GnT-V nor matriptase, because the levels of their expression
were quite low in anaplastic (undiﬀerentiated) carcinomas.
These results suggest that prolonged stabilization of matrip-
tase is stabilized through GnT-V-mediated glycosylation in
vivo, thus extending its halftime and permitting it to playJournal of Oncology 5
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Figure 4: Oligosaccharides involve in the regulation of thyroid function. The production of thyroid hormone by the thyroid gland is
regulated bythe hypothalamus and the pituitary gland. Hypothalamic thyrotropin-releasing hormone (TRH) induces the pituitary gland to
release thyroid-stimulating hormone (TSH) into the general circulation, whereby it reaches the thyroid gland and stimulates the production
and release of thyroid hormone [1].T4 is the predominant secretory product of the thyroid gland, with peripheraldeiodination of T4 to T3 in
the liver and kidneys supplying roughly 80% of the circulating T3. Both circulating T3 and T4 directly inhibit TSH synthesis and are released
independently;T4viaitsrapidconversiontoT3.CirculatingT4andT3areboundpredominantlytoserumproteins.FT3isthemetabolically
active form of thyroid hormone, whereas protein-bound T3 and T4 may be considered reservoirs of the hormone in equilibrium with the
metabolically active free hormone.
a role in the early phases of papillary carcinomas, but not
in the later phase of their progression. The staining pattern
of GnT-V was diﬀerent from that of Fut8 although GnT-
V and Fut8 are glycosyltransferases located on the Golgi
apparatus. GnT-V is cleaved by gamma secretase, resulting
in its secretion into the serum or conditioned medium [24].
The secreted type of GnT-V acts as an angiogenesis cofactor
[25].
5. Glypican3 andThyroid Cancer
Glypican 3 (GPC3) is one of the heparan sulfate proteogly-
cans (HSPGs) that are attached to the cell surface through
a glycosylphosphatidylinositol (GPI) anchor [26]. While
high expression of GPC3 is observed in fetal organs, it is
scarcely detected in adult tissues. Interestingly, the serum
levels of GPC3 measured by means of an enzyme-linked
immunosorbent assay were increased in patients with HCC
at 40∼53%. Since there was no correlation between the
GPC3 and alpha-feto protein levels, 82% of HCC patients
were positive for at least 1 of these 2 tumor-markers.
GPC3 was also identiﬁed as a tumor marker for melanomas
[27]. GPC3 is involved in several kinds of cell signaling
such as Wnt/Wingless, Hedgehog, TGF-β,a n dﬁ b r o b l a s t
growth factor, resulting in the stimulation of HCC growth
[28]. When we performed immunohistochemical analysis of
GPC3 in thyroid cancer [29], GPC3 was scarcely expressed
in normal thyroid glands, but was dramatically enhanced
in certain types of cancers including 100% of follicular
carcinomas (20/20 cases) and 70% of papillary carcinomas
(48/69 cases). Expression of GPC3 in follicular carcinomas
was signiﬁcantly higher than that of follicular adenomas (P
<.0019). In contrast, no expression of GPC 3 was observed
in 20 cases of anaplastic carcinomas. When expression of
GPC3 was investigated in 69 cases of papillary carcinomas
according to their clinical background, it was found to be
expressed at an early stage. These data prompted us to
perform experiments on transfection of GPC3 into thyroid
cancer cell lines to determine the biological function of
GPC3. When the GPC3 gene was transfected into a human
thyroid cancer cell line, TAD2, cell growth was dramatically
suppressed in the wild type of GPC3 transfectants, but not
markedly suppressed in the GPC3 oligosaccharide mutants
(Figure 3). This oligosaccharide of GPC3 is heparan sulfate
and the mutants were established by point mutation of
the amino acid sequences of GPC3 expression vectors. The
cell morphology dramatically changed with the transfection
of GPC3 with oligosaccharides but not GPC3 without
oligosaccharides. In the case of HCCs, oligosaccharides of
GPC3 were not linked to cell signaling or cell growth [28].
Further studies are required to characterize GPC3-mediated
cell signaling in thyroid cancer.6 Journal of Oncology
6.Perspective
The diﬀerential diagnosis of follicular adenocarcinoma from
follicular adenomas is the most important issue. In certain
cases, even pathological examination is not perfect. Galectin
3 has been reported in one of the candidate pathological
markers for a diﬀerential diagnosis [30]. Recently, we estab-
lished a quantitative ELISA assay for GPC3 and investigated
its clinical usefulness for the diagnosis of thyroid cancer
[31]. Galectin 3 binds to polylactosamine structures on N-
glycans and controls the function of cell surface receptors.
The polylactosamine structures are synthesized through
the reaction of GnT-V and the molecular mechanisms
underlying GnT-V-related cell signaling would be due to
galectin 3 [19]. It is important to determine the biological
functionofgalectin-3inthyroidcancer.Basically,thethyroid
is an endocrine organ that produces thyroid hormone.
Many factors control the release of thyroid hormone via
receptor-ligandmediatedsignaling(Figure4).Inthissystem,
oligosaccharides seem to be deeply involved, and therefore
control of thyroid function via oligosaccharides would be a
promisingresearchtarget.Manyhormonesincludingthyroid
hormone could be regulated through glycosylation [32].
In this review, we did not describe sialic acids in thyroid
carcinoma. Sialic acids are a terminal oligosaccharide on N-
/O-glycans and have a variety of biological functions [33].
While the biological signiﬁcance of sialic acids in thyroid
cancer remains unknown, changes in cellular sialylation have
been changed in malignant formation [34]. Transgenic or
knockout mice as to glycosyltransferases including sialyl-
transferases would be a powerful tool for determining the
oligosaccharide function in thyroid carcinogenesis directly.
Such mice should be mated with model mice for thyroid
cancer, if any.
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